$PGEN

Thomasian Harry Jr. sold $1.1M of PGEN

Thomasian Harry Jr. (Chief Financial Officer) sold 200,000 shares of PRECIGEN, INC. (PGEN) at an average of $5.57 ($5.53–$5.78, $1.11M total) across 2 trades over 2026-06-29 to 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Thomasian Harry Jr.
Published Jul 1, 2026, 10:22 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 1, 2026, 10:24 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PGEN
Neutral
medium confidence
Mentioned
$PGEN
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PGENNeutralLow
01

Why it matters

The disclosure provides a concrete datapoint on insider selling size, timing, and average sale price, but it does not include new operational, financial, or regulatory information.

02

Market read

Use the filing to update sentiment/positioning around PGEN, but expect limited fundamental read-through absent additional catalysts.

03

What to watch

Traders may overreact to insider sales; the key nuance here is the 10b5-1 structure and the relatively small dollar amount versus typical institutional flows.

Relevance 5/10Novelty 5/10Timing: filed after-hours on 2026-07-01; reflects sales executed 2026-06-29 to 2026-07-01

Background

This is an SEC Form 4 insider transaction disclosure for Precigen, Inc. (PGEN).

Company-level read

Ticker impact

$PGENNeutralMedium confidence
Context

Precigen CFO Thomasian Harry Jr. sold about 200,000 shares in open-market transactions totaling ~$1.11M under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect would be incremental and fade unless paired with other negative news.

Evidence & confidence

The filing is primary-source (Form 4) and quantifies size/price, but it is explicitly under a 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide driver.

None indicated.

None indicated.

Counterpoint

Because the trades were executed under a pre-arranged 10b5-1 plan, the sale may reflect routine liquidity needs rather than a bearish view on fundamentals.

Key entities

  • PRECIGEN, INC.

    Subject of the Form 4 insider transaction disclosure.

  • Thomasian Harry Jr.

    Chief Financial Officer who sold shares in open-market transactions.

  • 10b5-1 plan

    Pre-arranged plan noted as Yes, which can reduce interpretive signal.

Related articles

$PGENMed

PRECIGEN, INC. (PGEN): Results of Operations and Financial Condition

PRECIGEN, INC. (PGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 dp251262_ex9901.htm EXHIBIT 99.1 Exhibit 99.1 Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth · PAPZIMEOS ® net revenue of $53.1 million in the second quarter of 2026, more than double the prior quarter, reflec

$PGENMedAI 9/10

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Precigen (Nasdaq: PGEN) reported updated long-term durability data for PAPZIMEOS (zopapogene imadenovec-drba) in adults with recurrent respiratory papillomatosis. According to the company, 15 of 18 complete responders (83%) had ongoing complete responses for at least 36 months as of April 30, 2026, with 5 beyond 4 years; median duration not yet reached and no new safety events were observed. The FDA granted seven-year orphan drug market exclusivity.

$PGENMedAI 9/10

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Precigen (Nasdaq: PGEN) reported updated long-term durability data for PAPZIMEOS (zopapogene imadenovec-drba) in adults with recurrent respiratory papillomatosis (RRP), presented at the 2026 ASCO meeting. As of April 30, 2026, 15 of 18 complete responders (83%) had ongoing complete responses for ≥36 months without additional RRP treatment; 5 responders had responses beyond 4 years. Precigen said no new adverse safety events were observed. The FDA granted PAPZIMEOS seven-year orphan drug market e